CAJ | 학술논문

目的：探索肝功能异常的恶性血液病患者进行微移植的安全性，以及肝功能异常对微移植疗效可能的影响。方法入组患者共28例，微移植前肝功能异常者12例，对照组16例。所有病例均依据其原发病进行相应方案的预处理，接受亲缘HLA 5/10相合微移植。治疗中监测肝功能异常发生情况、造血恢复情况及原发病缓解情况。结果微移植前肝功能异常者在后续治疗中更倾向于发生肝功能异常，且总体肝功能异常持续时间较对照组长。微移植前肝功能异常者中性粒细胞和血小板的恢复的时间较对照无显著差异。微移植前原发病未完全缓解是治疗后未获完全缓解的危险因素（OR=22.500,95%CI.[2.031～249.239],P=0.011）。结论微移植前肝功能异常在后续治疗中更易发生肝功能异常，但不影响微移植过程中造血的恢复，也不是原发病未缓解的危险因素。
목적：탐색간공능이상적악성혈액병환자진행미이식적안전성，이급간공능이상대미이식료효가능적영향。방법입조환자공28례，미이식전간공능이상자12례，대조조16례。소유병례균의거기원발병진행상응방안적예처리，접수친연HLA 5/10상합미이식。치료중감측간공능이상발생정황、조혈회복정황급원발병완해정황。결과미이식전간공능이상자재후속치료중경경향우발생간공능이상，차총체간공능이상지속시간교대조조장。미이식전간공능이상자중성립세포화혈소판적회복적시간교대조무현저차이。미이식전원발병미완전완해시치료후미획완전완해적위험인소（OR=22.500,95%CI.[2.031～249.239],P=0.011）。결론미이식전간공능이상재후속치료중경역발생간공능이상，단불영향미이식과정중조혈적회복，야불시원발병미완해적위험인소。
Objective To explore the security of microtransplantation treatment for hematologic malignancies with abnormalities of liver function and the impact of hepatic dysfunction to efifcacy of microtransplantation. Methods A group of 28 patients were enrolled in this study, 12 patients were with abnormal liver function and 16 patients were as control group. They received pretreatment according to their malignancies respectively. The mobilized stem cells of HLA 5/10 matched donors were transfused to the patients within 24 to 72 hours after the pretreatment. The liver function, hematopoietic reconstitution and the remission of the malignancies were monitored during the treatment.Results More events of abnormalities of liver function were observed during the microtransplant treatment in patients with abnormal liver function before microtransplantation compared with the controls. And these patients were found to suffer from longer period of liver dysfunction than the controls. However, the neutrophils and platelets reconstitution were found no signiifcant difference in the two groups. Risk analysis indicated that the only risk factor for no complete remission after microtransplantation was not achieving complete remission before microtransplantation (OR=22.500, 95%CI. [2.031~249.239], P=0.011).ConclusionAbnormalities of liver function during microtransplantation tend to occur more in patients with abnormal liver function pre-microtransplantation, but the hematopoiesis is not impacted. Abnormality of liver function is not the risk factor of no complete remission of the primary malignancies.